MASCC Guidelines
Evidence-based clinical practice guidelines created by the MASCC study groups.
To access the full guidelines and guideline summary documents, simply log into your member account (for MASCC members) or provide your email address below (for non-members).
Antiemetics Study Group
MASCC/ESMO Antiemetic Guidelines (2023 Update)
Introduction to the 2023 guidelines update.
Herrstedt J et al. Supportive Care in Cancer (2023).
I Emetic classification of antineoplastic agents
Jordan K et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation. Supportive Care in Cancer (2023).
II Highly emetic chemotherapy
Herrstedt J et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer (2023).
III Moderately emetic chemotherapy
Scotté F et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Supportive Care in Cancer (2023).
IV Low or minimally emetic chemotherapy
Olver I et al. 2023 updated MASCC/ESMO consensus recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Supportive Care in Cancer (2023).
V Multiple-day, high-dose chemotherapy, refractory, break-through nausea and vomiting
Rapoport BL et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Supportive Care in Cancer (2023).
VI CAMs and non-pharmacological interventions
Molassiotis A et al. 2023 MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies. Supportive Care in Cancer (2023).
VII Radiotherapy-induced nausea and vomiting
Ruhlmann CH et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting. Supportive Care in Cancer (2023).
VII Resource-limited settings
Bosnjak SM et al. MASCC antiemetic consensus recommendations: resource-limited settings. Supportive Care in Cancer (2025).
IX Guidelines for patients
Affronti ML et al. MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients. Supportive Care in Cancer (2024).
Members,
Non Members,
Members,
Non Members,
Members,
Non Members,
Members,
Non Members,
Antiemetics in advanced cancer (MASCC updated guideline)
Davis M et al. Supportive Care in Cancer (2021).
Members,
Non Members,
Members,
Non Members,
Nausea and vomiting in malignant bowel obstruction
Davis M et al. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Supportive Care in Cancer (2021).
Members,
Non Members,
Members,
Non Members,
Bone and Musculoskeletal Study Group
Cancer Pain Subgroup
Immuno-Oncology Subgroup
Mucositis Study Group
Oncodermatology Study Group
Oral Care Study Group
Palliative Care Study Group
Survivorship Study Group
Endorsed Guidance
Telehealth in Oncology: ASCO Standards and Practice Recommendations
Zon R et al. JCO Oncology Practice (2021).
Bone Metastases and Exercise Knowledge Mobilization Team
Supporting publication:
Campbell KL et al. JCO Oncology Practice (2022).
Endorsement: Hart NH et al. Supportive Care in Cancer (2022)
Cancer-Related Fatigue Self-Management Support Practice Framework
Supporting publications:
Agbejule OA et al. Journal of Cancer Survivorship (2023).
Agbejule OA et al. International Journal of Nursing Studies (2022).
Agbejule OA et al. BMC Cancer (2021).
Agbejule OA et al. Supportive Care in Cancer (2023).
Patel P et al. European Journal of Cancer (2021).
Patel P et al. eClinicalMedicine (2024).
Lehrnbecher T et al. Journal of Clinical Oncology (2023).
Patel P et al. eClinicalMedicine (2023).
Patel P et al. Pediatric Blood Cancer (2023).
Patel P et al. Pediatric Blood Cancer (2022).
Patel P et al. European Journal of Cancer (2021).
